Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche's Ocrelizumab Strengthens Lead In Primary Progressive MS

This article was originally published in Scrip

Executive Summary

Sufferers of primary progressive multiple sclerosis (PPMS) - the rarer form of the neurological condition for which there is still no approved treatment - have had their hopes boosted by news Roche's CD20 antibody ocrelizumab won breakthrough therapy designation from the FDA, the first investigational therapy to do so in MS.

You may also be interested in...



Roche’s Highly Anticipated Ocrelizumab Delayed By Manufacturing Issues

US FDA extends review timeline for the multiple sclerosis BLA until March 28, 2017 to have time to review new information about commercial manufacturing process, Roche says.

Multiple Sclerosis: Close To Being Conquered

The development of a plethora of new medicines for multiple sclerosis over the past 10 years is truly remarkable. As well as the dozen or so agents now available to treat relapsing MS, the first potential product for the poorly treated condition, primary progressive MS, is nearing the market.

From Solanezumab To Solithromycin: What To Watch For In Q4

Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.

Topics

UsernamePublicRestriction

Register

SC064518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel